A traditional Chinese medicine composition for treating chronic atrophic gastritis and its application

Abstract

The present invention discloses a traditional Chinese medicine composition for treating chronic atrophic gastritis and its application, which is made from the following raw materials in parts by weight: 8 - 15 parts of Codonopsis pilosula, 8 - 15 parts of Atractylodes macrocephala, 8 - 15 parts of Poria cocos, 8 - 12 parts of Sparganium stoloniferum, 25 - 35 parts of Ficus hirta Vahl, 10 - 20 parts of Scutellaria barbata D. Don, 25 - 35 parts of Chinese yam, 8 - 15 parts of Dendrobium officinale, 6 - 10 parts of Pinellia ternata (Thunb.) Breit. var. pinellioides (Pritz.) Hsiao et K. C. Hsia, 8 - 15 parts of Bupleurum chinense DC., 8 - 15 parts of Curcuma aromatica Salisb., and 4 - 10 parts of Glycyrrhiza uralensis Fisch. The traditional Chinese medicine composition of the present invention has a definite therapeutic effect on chronic atrophic gastritis, providing a new drug option for the treatment of chronic atrophic gastritis. The traditional Chinese medicine composition of the present invention is a pure traditional Chinese medicine prescription, with good clinical efficacy and small toxic and side effects, and is suitable for clinical promotion and application.

Description

Technical Field

[0001] The present invention relates to the technical field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition for treating chronic atrophic gastritis and its application. Background Art

[0002] Chronic atrophic gastritis is one of the most common chronic digestive system diseases clinically and is generally considered a precancerous lesion state of gastric cancer. The clinical symptoms of chronic atrophic gastritis include stomachache, loss of appetite, weight loss, etc. The pathological features are chronic inflammation of the gastric mucosa and reduction or loss of cells in the gastric glandular part, often accompanied by intestinal metaplasia, which will ultimately lead to the occurrence of gastric cancer. Reversing precancerous lesions and improving the state of chronic atrophic gastritis should become an important means to avoid the occurrence of gastric cancer. The pathogenesis of chronic atrophic gastritis is currently unclear, but it is generally considered to be caused by repeated damage to the gastric mucosa by physical and chemical factors, Helicobacter pylori infection and other factors.

[0003] Currently, Western medicine has no specific therapy for chronic atrophic gastritis. The treatment methods include eradicating Helicobacter pylori, protecting the gastric mucosa, promoting gastric motility (such as domperidone), supplementing mucosal nutrition (such as coenzyme complex), etc. The curative effect is poor, the recurrence rate is high, and it is difficult to cure. Therefore, there is an urgent need to develop a new traditional Chinese medicine composition for treating chronic atrophic gastritis. Traditional Chinese medicine has a long history and unique advantages in the treatment of gastrointestinal diseases. Summary of the Invention

[0004] In view of this, the purpose of the present invention is to provide a traditional Chinese medicine composition for treating chronic atrophic gastritis, which has a good therapeutic effect on chronic atrophic gastritis.

[0005] The purpose of the present invention is achieved through the following technical solutions:

[0006] A traditional Chinese medicine composition for treating chronic atrophic gastritis is made from the following raw materials in parts by weight:

[0007] Codonopsis pilosula 8 - 15 parts, Atractylodes macrocephala 8 - 15 parts, Poria cocos 8 - 15 parts, Sparganium stoloniferum 8 - 12 parts, Ficus hirta 25 - 35 parts, Scutellaria barbata 10 - 20 parts, Dioscorea opposita 25 - 35 parts, Dendrobium officinale 8 - 15 parts, Pinellia ternata 6 - 10 parts, Bupleurum chinense 8 - 15 parts, Curcuma aromatica 8 - 15 parts, Glycyrrhiza uralensis 4 - 10 parts.

[0008] As a further preferred scheme, the traditional Chinese medicine composition for treating chronic atrophic gastritis is made from the following raw materials in parts by weight:

[0009] Codonopsis pilosula 10 parts, Atractylodes macrocephala 10 parts, Poria cocos 10 parts, Sparganium stoloniferum 10 parts, Ficus hirta 30 parts, Scutellaria barbata 15 parts, Dioscorea opposita 30 parts, Dendrobium officinale 10 parts, Pinellia ternata 9 parts, Bupleurum chinense 10 parts, Curcuma aromatica 10 parts, Glycyrrhiza uralensis 6 parts.

[0010] The Chinese medicine composition of the present invention comes from the clinical experience prescription, with Codonopsis pilosula, Atractylodes macrocephala and Poria cocos as the main ingredients. These three medicines are sweet in taste, all enter the spleen meridian, belong to qi-tonifying medicines, and are used in combination. The main effects are to invigorate qi and strengthen the spleen, warm but not dry, tonic but not harsh, and slowly, which conforms to the characteristics of spleen and stomach liking sweetness and mild medication. The spleen likes dryness and hates dampness, and spleen deficiency is prone to dampness. In addition to strengthening the spleen, Atractylodes macrocephala and Poria cocos can also dry dampness and promote diuresis, and are more suitable for patients with spleen deficiency and dampness. Chronic gastritis is seen in poor appetite, fatigue, hunger and loss of appetite, and other symptoms of spleen deficiency and yin deficiency of stomach qi. The treatment should invigorate the spleen and invigorate qi, but it should not be harsh, and the emphasis should be on tonifying the middle qi. Five-fingered ginseng, Chinese yam, Tripterygium wilfordii, and Curcuma zedoaria are the assistants. Five-fingered ginseng, also known as Nanqi, is a Lingnan local medicinal material. It has the effect of nourishing qi and dispelling dampness, and assists the main medicine to nourish without stagnation; Chinese yam nourishes the spleen and produces body fluid, and assists the main medicine to nourish qi, and takes into account the chronic atrophic gastritis patients with long-term illness that damages yin and insufficient stomach yin; chronic atrophic gastritis has a long course of disease, and the disease becomes blood stasis after a long time, and it is common to have a dark tongue, stabbing pain in the stomach, and the pain is fixed. Tripterygium wilfordii and Curcuma zedoaria can promote blood circulation and relieve pain, and Curcuma zedoaria can promote qi and relieve depression, and take into account the adjustment of the emotions of patients with long-term illness. Scutellaria barbata, Dendrobium officinale, Pinellia ternata, and Bupleurum chinense are the assistants. Scutellaria barbata is pungent, bitter, and cold. It has the effects of clearing away heat and detoxifying, promoting blood circulation and removing blood stasis, and relieving swelling and pain. It is the counter-adjuvant of this prescription, making this prescription warm and nourishing without being warm and dry. It slightly adds the power of attack and dispersion to the tonic medicine, expelling evil without hurting the body. It can still expel evil by detoxifying and reducing swelling. It is suitable for chronic gastritis accompanied by mucosal atrophy, intestinal metaplasia, and dysplasia. Dendrobium is sweet and belongs to the stomach meridian. It nourishes yin and benefits the stomach. It assists yam in nourishing stomach fluid. Spleen deficiency fails to transport and transform, and the fine food accumulates, forming phlegm and dampness in the middle. Pinellia and Bupleurum are used to promote qi, eliminate stagnation, and dry dampness. Bupleurum enters the liver meridian and is a good medicine for promoting qi and soothing the liver. It assists the whole prescription in replenishing the middle and helps Curcuma regulate emotions. Licorice is used to replenish qi and harmonize the middle, and harmonize all the medicines. It is a guiding medicine. The whole prescription is based on the methods of invigorating Qi and strengthening the spleen, promoting blood circulation and dispersing blood stasis, taking into account the methods of regulating Qi, dispersing nodules and nourishing Yin. It is suitable for patients with spleen deficiency and blood stasis syndrome in chronic atrophic gastritis, and has a definite therapeutic effect on chronic atrophic gastritis.

[0011] The present invention also provides a method for preparing the above-mentioned Chinese medicine composition for treating chronic atrophic gastritis, comprising the following steps:

[0012] Add 6-10 times amount of water to each raw material and boil twice, each time for 1-2 hours. Combine the extracts, concentrate and filter to obtain the product.

[0013] The present invention also provides the use of the above-mentioned traditional Chinese medicine composition in preparing medicine for treating chronic atrophic gastritis.

[0014] As a further preferred embodiment, the chronic atrophic gastritis is chronic atrophic gastritis of spleen deficiency and blood stasis type.

[0015] As a further preferred embodiment, the chronic atrophic gastritis is chronic atrophic gastritis accompanied by mucosal atrophy, intestinal metaplasia, and dysplasia.

[0016] As a further preferred embodiment, the drug comprises a traditional Chinese medicine composition in an effective amount and a pharmaceutically acceptable carrier. The drug of the present invention can be prepared into a suitable dosage form by conventional methods in the art. Preferably, the dosage form of the drug is a mixture, tablet, capsule, pill, powder or granule.

[0017] Compared with the prior art, the present invention has the following excellent effects:

[0018] In the present invention, a rat model of chronic atrophic gastritis was established by the MNNG method. The results showed that the traditional Chinese medicine composition of the present invention could significantly improve the gastric injury of rats with chronic atrophic gastritis induced by MNNG, improve the weight loss of rats, the degree of gastric atrophy and the gastric tissue morphology. Moreover, it could significantly reduce the level of PG II, increase PG I and GAS, and reduce the content of the inflammatory factor IL6, indicating that it could significantly improve the levels of gastric hormones and inflammatory factors in rats with chronic atrophic gastritis. The above results show that the traditional Chinese medicine composition of the present invention has a definite therapeutic effect on chronic atrophic gastritis and provides a new drug option for the treatment of chronic atrophic gastritis.

[0019] The traditional Chinese medicine composition for treating chronic atrophic gastritis in the present invention is a pure traditional Chinese medicine prescription, which has good clinical efficacy and small toxic and side effects, and is suitable for clinical promotion and application. Description of the Drawings

[0020] Figure 1 Effect of Shenzhu Yangwei Prescription on the body weight of rats with chronic atrophic gastritis;

[0021] Figure 2 Effect of Shenzhu Yangwei Prescription on the gastric organ index of rats with chronic atrophic gastritis;

[0022] Figure 3 Gastric appearance diagrams of rats in each group;

[0023] Figure 4 Effect of Shenzhu Yangwei Prescription on serum biochemical indexes of rats with chronic atrophic gastritis;

[0024] Figure 5 Effect of Shenzhu Yangwei Prescription on serum inflammatory factor indexes of rats with chronic atrophic gastritis.

[0025] Wherein Ctrl: blank group; Model: model group; Vitacoenzyme: coenzyme group; SZYW-L: low-dose group of Shenzhu Yangwei Prescription; SZYW-M: high-dose group of Shenzhu Yangwei Prescription. Detailed Embodiments

[0026] The present invention will be further described below through specific embodiments. The following embodiments are specific embodiments of the present invention, but the embodiments of the present invention are not limited by the following embodiments.

[0027] Example 1:

[0028] A traditional Chinese medicine composition for treating chronic atrophic gastritis is made from the following raw materials in parts by weight:

[0029] 10 parts of Codonopsis pilosula, 10 parts of Atractylodes macrocephala, 10 parts of Poria cocos, 10 parts of Sparganium stoloniferum, 30 parts of Ficus hirta, 15 parts of Scutellaria barbata, 30 parts of Dioscorea opposita, 10 parts of Dendrobium officinale, 9 parts of Pinellia ternata prepared with Rhizoma Zingiberis Recens, 10 parts of Bupleurum chinense, 10 parts of Curcuma aromatica, 6 parts of Glycyrrhiza uralensis.

[0030] Its preparation method is as follows: Add 8 times the amount of water to each raw material and decoct for 1.5 h, collect the extract. Add 6 times the volume of water to the medicinal residues and boil for 1 hour, combine the extracts, concentrate at 60 °C, and filter to obtain.

[0031] Example 2:

[0032] A traditional Chinese medicine composition for treating chronic atrophic gastritis is made from the following raw materials in parts by weight:

[0033] 12 parts of Codonopsis pilosula, 12 parts of Atractylodes macrocephala, 12 parts of Poria cocos, 8 parts of Sparganium stoloniferum, 25 parts of Ficus hirta, 10 parts of Scutellaria barbata, 35 parts of Dioscorea opposita, 8 parts of Dendrobium officinale, 6 parts of Pinellia ternata prepared with Rhizoma Zingiberis Recens, 8 parts of Bupleurum chinense, 15 parts of Curcuma aromatica, 4 parts of Glycyrrhiza uralensis.

[0034] Its preparation method is the same as that of Example 1.

[0035] Example 3:

[0036] A traditional Chinese medicine composition for treating chronic atrophic gastritis is made from the following raw materials in parts by weight:

[0037] 15 parts of Codonopsis pilosula, 15 parts of Atractylodes macrocephala, 15 parts of Poria cocos, 12 parts of Sparganium stoloniferum, 35 parts of Ficus hirta, 20 parts of Scutellaria barbata, 25 parts of Dioscorea opposita, 12 parts of Dendrobium officinale, 10 parts of Pinellia ternata prepared with Rhizoma Zingiberis Recens, 15 parts of Bupleurum chinense, 8 parts of Curcuma aromatica, 5 parts of Glycyrrhiza uralensis.

[0038] Its preparation method is the same as that of Example 1.

[0039] Test Example 1: Pharmacodynamic study on treating chronic atrophic gastritis

[0040] 1. Experimental materials

[0041] 1.1 Drugs

[0042] Shenzhu Yangwei Prescription: (10 g of Codonopsis pilosula, 10 g of Atractylodes macrocephala, 10 g of Poria cocos, 10 g of Sparganium stoloniferum, 30 g of Ficus hirta, 15 g of Scutellaria barbata, 30 g of Dioscorea opposita, 10 g of Dendrobium officinale, 9 g of Pinellia ternata prepared with Rhizoma Zingiberis Recens, 10 g of Bupleurum chinense, 10 g of Curcuma aromatica, 6 g of Glycyrrhiza uralensis) was purchased from Nanjing Tongrentang Pharmacy, Dongguan City, Guangdong Province. Wei Meisu (CAS: 83 - 88 - 5, Lot#: C14376028) was purchased from Shanghai Macklin Biochemical Technology Co., Ltd.

[0043] Preparation method: Add 8 times the amount of water to the crude drug and decoct for 1.5 h, collect the extract. Add 6 times the volume of water to the drug residue and boil for 1 hour, combine the extracts, concentrate at 60 °C, and filter to obtain the concentrated solution.

[0044] 1.2 Reagents

[0045] MNNG (CAS: 70-25-7, Lot#: C15811079) was purchased from Shanghai Macklin Biochemical Co., Ltd.

[0046] 1.3 Animals

[0047] Male SD rats (purchased from Liaoning Changsheng Biotechnology Co., Ltd.) weighed 150 - 170 g. The rats were caged in the Experimental Animal Center of Guangdong Medical University (Dongguan Campus) at a room temperature of 24 - 25 °C, humidity of 70 - 75%, 12-hour light / dark cycle, and free access to food and water.

[0048] 2. Experimental methods

[0049] After 7 days of adaptive feeding with standard diet and water (24 - 25 °C, humidity 70 - 75%, 12-hour light / dark cycle), the rats were randomly divided into 2 groups, including a blank group and a model group. The blank group drank water freely, and the model group was continuously orally administered a 200 μg / ml MNNG solution combined with irregular feeding (fasting for one day and feeding for one day) for 8 weeks. After 8 weeks, the rats in the model group were randomly divided into 4 groups, namely the model group, the positive drug coenzyme Q10 group (0.6 g / kg), the low-dose group of Shenzhu Yangwei Fang (7.191 g / kg), and the high-dose group of Shenzhu Yangwei Fang (14.39 g / kg). The low-dose and high-dose groups of Shenzhu Yangwei Fang were intragastrically administered the corresponding doses of the drug at 1 ml / 100 g per day. The model group and the positive drug group were respectively given an equivalent amount of normal saline and coenzyme Q10, and the drug administration continued for 4 weeks. At the end of the drug administration period, the animals were anesthetized and blood was collected from the abdominal aorta, and then the animals were sacrificed and the rat stomachs were taken. Calculate the organ index: Organ index = organ mass / rat body weight.

[0050] Centrifuge at 3000 rpm for 10 min after blood collection, collect the upper-layer serum, aliquot and store it at -80 °C. Detect the contents of PG I, PG II, GAS, IL6, etc. in the serum according to the instructions of the ELISA kit.

[0051] Use Graphpad Prism 7.0 statistical analysis software to analyze the results. Each group of data is expressed, and one-way ANOVA is used for comparison between samples.

[0052] 3. Results and discussion

[0053] 3.1 Effect of Shenzhu Yangwei Fang on the body weight of rats with chronic atrophic gastritis

[0054] As shown in Table 1 and Figure 1 as shown, after the 12-week modeling and drug administration period ended, the weight gain rate of the model group was slower than that of the blank group. There was a significant difference in weight between the model group and the blank group at the 12th week (P < 0.001). The low-dose and high-dose groups of the Shenzhu Yangwei formula could increase the weight of rats with chronic atrophic gastritis (P < 0.01).

[0055] Table 1. Effects of the Shenzhu Yangwei formula on the weight of rats with chronic atrophic gastritis (n = 8)

[0056]

[0057]

[0058] Note: #p < 0.05, ##p < 0.01, p < 0.001 vs blank control group, the difference was statistically significant. *p < 0.05, **p < 0.01, ***p < 0.001 vs model group, the difference was statistically significant.

[0059] 3.2 Effects of the Shenzhu Yangwei formula on the gastric organ index of rats with chronic atrophic gastritis

[0060] As shown in Table 2 and Figure 2 as shown, the gastric organ index of rats in the model group was significantly increased compared with that of the blank group (P < 0.001), while the low-dose and high-dose groups of the Shenzhu Yangwei formula could significantly reduce the gastric organ index of rats with chronic atrophic gastritis (P < 0.01), alleviating the degree of gastric atrophy.

[0061] Table 2. Effects of the Shenzhu Yangwei formula on the gastric organ index of rats with chronic atrophic gastritis (n = 8)

[0062]

[0063] Note: #p < 0.05, ##p < 0.01, p < 0.001 vs blank control group, the difference was statistically significant. *p < 0.05, **p < 0.01, ***p < 0.001 vs model group, the difference was statistically significant.

[0064] 3.3 Effects of the Shenzhu Yangwei formula on the gastric appearance of rats with chronic atrophic gastritis

[0065] As Figure 3 shown, the gastric mucosa color of rats in the blank group was dark red, the gastric folds were deeper, and the mucosal layer was rich; the color of the gastric tissue of rats in the model group was lighter than that of the blank group, and the gastric folds were shallower and fewer. The gastric tissue of rats in the low-dose and high-dose groups of the Shenzhu Yangwei formula was darker in color and had more gastric folds compared with the model group.

[0066] 3.4 Effects of the Shenzhu Yangwei formula on the serum biochemical indexes of rats with chronic atrophic gastritis

[0067] As shown in Table 3 and Figure 4 as follows, compared with the blank group, the contents of PGI and GAS in the model group decreased, while the content of PGII increased (P<0.01). The low-dose and high-dose groups of the Shenzhu Yangwei formula could effectively increase the contents of PGI and GAS (P<0.001), and decrease the content of PGII (P<0.01).

[0068] Table 3. Effects of the Shenzhu Yangwei formula on serum biochemical indexes in rats with chronic atrophic gastritis (n=6)

[0069]

[0070]

[0071] Note: #p<0.05, ##p<0.01, p<0.001 vs the blank control group, the difference was statistically significant. *p<0.05, **p<0.01, ***p<0.001 vs the model group, the difference was statistically significant.

[0072] As shown in Table 4 and Figure 5 as follows, compared with the blank group, the content of IL-6 in the model group increased. The low-dose and high-dose groups of the Shenzhu Yangwei formula could significantly decrease the level of IL-6 and reduce the inflammation level in rats with chronic atrophic gastritis.

[0073] Table 4. Effects of the Shenzhu Yangwei formula on serum inflammatory factor levels in rats with chronic atrophic gastritis (n=6)

[0074]

[0075] Note: #p<0.05, ##p<0.01, p<0.001 vs the blank control group, the difference was statistically significant. *p<0.05, **p<0.01, ***p<0.001 vs the model group, the difference was statistically significant.

[0076] 4. Conclusion

[0077] The traditional Chinese medicine composition (Shenzhu Yangwei formula) of the present invention can effectively improve the weight loss and gastric atrophy degree in rats with chronic atrophic gastritis, improve the reduction of gastric folds in rats with atrophic gastritis, increase the contents of PGI and GAS in rats with chronic atrophic gastritis, decrease the contents of PGII and IL-6 levels, indicating that it can improve the gastric hormone level and inflammation level in rats with chronic atrophic gastritis. In summary, the Shenzhu Yangwei formula can effectively reverse MNNG-induced chronic atrophic gastritis.

[0078] Clinical cases:

[0079] (1) Ms. Zhuang, 40 years old, was initially diagnosed on October 21, 2022. The patient was troubled by repeated abdominal distension. A gastroscopy was performed in June 2022, which indicated chronic atrophic gastritis. The traditional Chinese medicine diagnosis was stomach stuffiness, with the syndrome of spleen deficiency and blood stasis. The traditional Chinese medicine composition in this patent was used, decocted and taken orally, 1 dose per day. After 1 year of treatment, a gastroscopy was reexamined on October 12, 2023: chronic non-atrophic gastritis with erosion. Pathological diagnosis: (gastric antrum) mild chronic non-atrophic gastritis with focal erosion. After 2 months of follow-up, the patient has stopped taking the medicine for 2 months currently, and no symptom recurrence has been seen.

[0080] (2) Mr. Wei, 47 years old, was initially diagnosed on June 18, 2021. He visited the doctor due to repeated dull pain in the abdomen. Gastroscopy in November 2020: chronic superficial gastritis with erosion, and the pathology indicated intestinal metaplasia (+). The traditional Chinese medicine diagnosis was epigastric pain, with the syndrome of spleen deficiency and blood stasis. The traditional Chinese medicine composition in this patent was used, decocted and taken orally, 1 dose per day. After 5 months of treatment, a gastroscopy was reexamined on November 19, 2021: erosive gastritis with mild intestinal metaplasia, pathology: chronic gastritis of the mucosa, intestinal metaplasia (+). The traditional Chinese medicine composition in this patent was continued to be used, decocted and taken orally, 1 dose per day. After 11 months of treatment, a gastroscopy was reexamined on October 28, 2022: erosive gastritis. After 1 year of follow-up, there was no abdominal discomfort.

[0081] (3) Mr. Yi, 50 years old, was initially diagnosed on May 20, 2022. The patient complained of upper abdominal distension for 20 years. Gastroscopy on August 20, 2022 showed: chronic atrophic gastritis C1 with erosion, colonoscopy: multiple polyps in the colorectum. The traditional Chinese medicine diagnosis was stomach stuffiness, with the syndrome of spleen deficiency and blood stasis. The traditional Chinese medicine composition in this patent was used, decocted and taken orally, 1 dose per day. After 9 months of treatment, a gastroscopy was reexamined on May 31, 2023: erosive gastritis, and no mucosal atrophy change was seen in the pathology. The current symptoms have been significantly relieved.

[0082] (4) Ms. Tan, 54 years old, was initially diagnosed on August 26, 2022. Due to upper abdominal pain for nearly 3 years and a history of chronic atrophic gastritis with intestinal metaplasia, the traditional Chinese medicine diagnosis was epigastric pain, with the syndrome of spleen deficiency and blood stasis. The traditional Chinese medicine composition in this patent was used, decocted and taken orally, 1 dose per day. After 8 months of treatment, a gastroscopy was reexamined on April 18, 2023: chronic non-atrophic gastritis. After 6 months of follow-up, no symptom recurrence was seen.

[0083] (5) Ms. Qin, 41 years old, was initially diagnosed on July 16, 2021. She visited the doctor due to dull pain in the epigastrium. Gastroscopy on July 16, 2021: erosive gastritis with intestinal metaplasia and atypical changes, and the pathological result indicated chronic inflammation of the gastric antrum mucosa with erosion, intestinal metaplasia and atypical changes. The traditional Chinese medicine diagnosis was epigastric pain, with the syndrome of spleen deficiency and blood stasis. The traditional Chinese medicine composition in this patent was used, decocted and taken orally, 1 dose per day. After 1 year of treatment, a gastroscopy was reexamined on July 1, 2022: chronic non-atrophic gastritis. After 1 year of follow-up, no recurrence was seen.

[0084] Ms. Lin, 60 years old, was initially diagnosed on June 23, 2022. She came for medical treatment due to abdominal distension. On July 30, 2021, the gastroscopy in our hospital showed chronic gastritis with severe intestinal metaplasia. On March 28, 2022, the gastroscopy in our hospital showed chronic atrophic gastritis C1 with erosion and intestinal metaplasia. The pathological result was chronic atrophic gastritis of the gastric antrum, with erosion and intestinal metaplasia (++). The traditional Chinese medicine diagnosis was stomach stuffiness, syndrome of spleen deficiency and blood stasis. The traditional Chinese medicine composition in this patent was used, decocted and taken orally, 1 dose per day. After 8 months of treatment, the gastroscopy was reexamined on April 7, 2023, showing chronic atrophic gastritis, and the pathology indicated mild chronic atrophic gastritis with intestinal metaplasia. The current symptoms have been significantly relieved.

Claims

1. A traditional Chinese medicine composition for treating chronic atrophic gastritis, characterized in that, it is made from the following raw materials in parts by weight: 8 - 15 parts of Codonopsis pilosula, 8 - 15 parts of Atractylodes macrocephala, 8 - 15 parts of Poria cocos, 8 - 12 parts of Sparganium stoloniferum, 25 - 35 parts of Ficus hirta Vahl, 10 - 20 parts of Scutellaria barbata, 25 - 35 parts of Chinese yam, 8 - 15 parts of Dendrobium officinale, 6 - 10 parts of Pinellia ternata (processed), 8 - 15 parts of Bupleurum chinense, 8 - 15 parts of Curcuma aromatica, 4 - 10 parts of Glycyrrhiza uralensis Fisch.

2. The traditional Chinese medicine composition for treating chronic atrophic gastritis according to claim 1, characterized in that, it is made from the following raw materials in parts by weight: 10 parts of Codonopsis pilosula, 10 parts of Atractylodes macrocephala, 10 parts of Poria cocos, 10 parts of Sparganium stoloniferum, 30 parts of Ficus hirta Vahl, 15 parts of Scutellaria barbata, 30 parts of Chinese yam, 10 parts of Dendrobium officinale, 9 parts of Pinellia ternata (processed), 10 parts of Bupleurum chinense, 10 parts of Curcuma aromatica, 6 parts of Glycyrrhiza uralensis Fisch.

3. The preparation method of the traditional Chinese medicine composition for treating chronic atrophic gastritis according to claim 1 or 2, characterized in that, it includes the following steps: Adding 6 - 10 times the amount of water to decoct the raw materials twice, each time for 1 - 2 hours, combining the extraction solutions, concentrating, and filtering to obtain the product.

4. The application of the traditional Chinese medicine composition according to claim 1 or 2 in the preparation of a drug for treating chronic atrophic gastritis.

5. The application according to claim 4, characterized in that, the chronic atrophic gastritis is spleen - deficiency and blood - stasis type chronic atrophic gastritis.

6. The application according to claim 4, characterized in that, the chronic atrophic gastritis is chronic atrophic gastritis accompanied by mucosal atrophy, intestinal metaplasia, and dysplasia.

7. The application according to claim 4, characterized in that, the drug is made from an effective content of the traditional Chinese medicine composition and a pharmaceutically acceptable carrier.

8. The application according to claim 7, characterized in that, the dosage form of the drug is mixture, tablet, capsule, pill, powder or granule.

Images